Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis

Li, Philip Kam-Tao; Chow, Kai‐Ming; Wong, Teresa Yuk‐Hwa; Leung, Chi‐Bon; Szeto, Cheuk‐Chun

doi:10.7326/0003-4819-139-2-200307150-00010

Cited by 258 publications

(193 citation statements)

References 29 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…Efforts to preserve residual renal function are likely to be beneficial for both MHD and PD patients. Randomized, controlled trials have demonstrated that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are renoprotective among PD patients (93,94). Even though there is no evidence that slowing the rate of decline of residual renal function translates into a survival benefit for maintenance dialysis patients, a controlled trial to test this hypothesis is probably unethical.…”

Section: Focus On the Future: Efforts To Continue To Improve Outcomesmentioning

confidence: 99%

Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?

Khawar

Kalantar-Zadeh

et al. 2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

In the past decade, peritoneal dialysis use among patients with end-stage renal disease has declined in many countries. Studies from the United States indicate that many academic centers do not have adequate resources to train fellows, most incident dialysis patients are not offered peritoneal dialysis, and more than half of dialysis clinics do not have the infrastructure to support peritoneal dialysis. Some are concerned that the outcomes of peritoneal dialysis and maintenance hemodialysis patients may not be equivalent, a notion that is not supported by outcome studies. Given the effect of modality selection on patients' lifestyle, attempts to conduct a randomized, controlled comparison of maintenance hemodialysis and peritoneal dialysis have been unsuccessful. Most observational studies showed that peritoneal dialysis is associated with a survival advantage that diminishes over time; it is unclear whether any of the differences over time are attributable to the modality. Between 1996 and 2003, the early outcomes of peritoneal dialysis patients further improved, whereas those for maintenance hemodialysis patients remained unchanged. Differences in outcomes may be due to residual statistical confounding; however, several biologic mechanisms can be postulated: The early survival advantage may be related to the better preservation of residual renal function with peritoneal dialysis, and the diminution of the survival advantage may be related to worsened volume control. There is a need for large observational and interventional studies among peritoneal dialysis patients to sustain and enforce the improvements in both dialysis therapies.

show abstract

Section: Focus On the Future: Efforts To Continue To Improve Outcomesmentioning

confidence: 99%

Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?

Khawar

Kalantar-Zadeh

et al. 2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…However, furosemide has been used successfully to achieve diuresis and improved fluid balance, without influencing residual renal function [44]. The use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers in adult PD patients suggests a positive effect on preserving residual renal function [45,46]. Results of the Effect of Strict Blood Pressure Control and ACE Inhibition on Progression of CRF in Pediatric Patients (ESCAPE) trial evaluating the effect of ramipril on estimated glomerular filtration rate (eGFR) and proteinuria in children with CKD, including a small cohort of PD patients, are awaited.…”

Section: Residual Renal Functionmentioning

confidence: 99%

Long-term outcome of chronic dialysis in children

et al. 2005

View full text Add to dashboard Cite

As the prevalence of children on renal replacement therapy (RRT) increases world wide and such therapy comprises at least 2% of any national dialysis or transplant programme, it is essential that paediatric nephrologists are able to advise families on the possible outcome for their child on dialysis. Most children start dialysis with the expectation that successful renal transplantation is an achievable goal and will provide the best survival and quality of life.

show abstract

“…b) Prevention of hypotensive episodes c) Use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARBs) reduces the rate of decline in RRF and possibly delays the development of complete anuria in patients performing PD 40,41 .…”

Section: Protection Of Rrfmentioning

confidence: 99%

Role of Ultrafiltration in Peritoneal Dialysis: A Review

Kumar¹

2017

jmscr

View full text Add to dashboard Cite

Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis

Cited by 258 publications

References 29 publications

Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?

Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?

Long-term outcome of chronic dialysis in children

Role of Ultrafiltration in Peritoneal Dialysis: A Review

Contact Info

Product

Resources

About